Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677165 | 1.00 | MEN1 (0.69) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Bromide SCHEMBL2995963 | 0.98 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Hydrochloric Acid SCHEMBL8752465 | 0.98 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL2565442 | 0.89 | MEN1 (0.69) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL17416718 | 0.88 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3445036 | 0.88 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL3445035 | 0.88 | MEN1 (0.67) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL10899938 | 0.86 | MEN1 (0.65) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| Phytic Acid SCHEMBL1360053 | 0.86 | MEN1 (0.52) | MEN1KMT2ACYP1A2HRH1CYP2C19 | |
| SCHEMBL1644173 | 0.85 | MEN1 (0.68) | MEN1KMT2ACYP1A2HRH1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098860-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | SOC DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE S E C (CA) | 2026-04-09 | — | — | US | claimed |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MARVELBIOME INC (US) | 2026-04-02 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2025-07-29 | — | — | US | claimed |
| EP-4587818-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES ET GENIE, S.E.C. (CA) | 2025-07-23 | — | — | EP | claimed |
| EP-4587116-A2 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | MarvelBiome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| CN-120092177-A | Sensor, kit and method for detecting biomarkers in saliva | 索科普哈应用研究产品商业化基因科学有限合伙公司 | 2025-06-03 | — | — | CN | claimed |
| WO-2025054048-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING LIPID AND CHOLESTEROL METABOLISM ASSOCIATED DISEASES, DISORDERS, AND CONDITIONS | MarvelBiome, Inc. (US) | 2025-03-13 | — | — | WO | claimed |
| CN-119595817-A | Helicobacter pylori infection related metabolic marker combination for predicting stomach cancer incidence risk and application thereof | 南京医科大学 | 2025-03-11 | — | — | CN | claimed |
| CN-113960312-B | Serum metabolism marker for diagnosing benign and malignant lung nodules and application thereof | 上海市第一人民医院 | 2025-03-04 | — | — | CN | claimed |
| US-6149924-A | FOR TOPICAL APPLICATION | BIOMED RESEARCH & TECHNOLOGIES, INC. (US) | 2000-11-21 | — | — | US | claimed |
| WO-2000004870-A2 | COMPOSITION FOR ENHANCING EPIDERMAL LIPID PRODUCTION | BIOMED RESEARCH AND TECHNOLOGIES, INC. (US) | 2000-02-03 | — | — | WO | claimed |
| US-RE36331-E | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1999-10-05 | — | — | US | claimed |
| US-5576348-A | Pharmaceutical preparation comprising an acylcarnitine | KURATSUNE HIROHIKO (JP) | 1996-11-19 | — | — | US | claimed |
| US-5496821-A | Use of L-carnitine and alkanoyl L-carnitines in the storage of blood for transfusions and stabilizing solutions containing them | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1996-03-05 | — | — | US | claimed |
| EP-0681839-A2 | A pharmaceutical preparation comprising an acylcarnitine | Kuratsune, Hirohiko (JP) | 1995-11-15 | — | — | EP | claimed |
| EP-0376899-B1 | USE OF L-CARNITINE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE THERAPEUTICAL TREATMENT OF PERIPHERAL NEUROPATHIES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1993-08-04 | — | — | EP | claimed |
| US-5227518-A | L-CARNITINE DERIVATIVES AS THERAPEUTICAL AGENTS FOR TREATING MYOPATHIES AND NEURONAL DEGENERATION AND FOR INHIBITING PROTEOLYSIS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 1993-07-13 | — | — | US | claimed |
| EP-0516594-A1 | L-carnitine derivatives as therapeutical agents for treating myopathies and neuronal degeneration and for inhibiting proteolysis | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1992-12-02 | — | — | EP | claimed |
| EP-0376899-A2 | Use of L-carnitine derivatives for the manufacture of a medicament for the therapeutical treatment of peripheral neuropathies | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1990-07-04 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370173-B2 | Pet food compositions that modulate vitamin D and bone mineral content in a companion animal | CYP24A1, GC, VDR | MEN1 165/4885KMT2A 3472/4885CYP1A2 2546/4885 |
| US-20260091067-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING INSULIN-ASSOCIATED DISEASES | IAPP, GPR119, FAHD1 | MEN1 361/4885KMT2A 2945/4885CYP1A2 862/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | MEN1 3658/4885KMT2A 119/4885CYP1A2 4682/4885 |
| US-20260098860-A1 | SENSOR, KIT, AND METHOD FOR BIOMARKER DETECTION IN SALIVA | MB, TAS2R40, MUC1 | MEN1 1646/4885KMT2A 581/4885CYP1A2 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.